Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ).
Zylox-Tonbridge Medical Technology reported strong 2025 results, with revenue rising 35.1% year on year to RMB1.06 billion and profit more than doubling, supported by a gross margin improvement to 72.1%. Growth was driven by both neurovascular and peripheral vascular interventional products, with neurovascular sales up 28.0% on broader hospital penetration and nationwide roll-out of newer products, while peripheral vascular revenue surged 50.3% on rapid uptake of established devices and the commercial launch of new venous stent and closure systems.
The company’s ability to expand volumes and shift toward higher-margin innovative products helped offset pricing pressure from centralized procurement, suggesting resilient profitability despite an increasingly regulated pricing environment. Its expanding product mix and strengthened distribution network appear to be bolstering competitive positioning in China’s interventional device market, enhancing scale advantages for both its operations and suppliers and potentially supporting sustained earnings growth.
The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a China-based medical device company focused on interventional neurovascular and peripheral vascular products. Its portfolio includes flow diverters, intracranial catheters, embolization coils, guidewires, drug-coated balloons, venous stents, and closure systems, targeting hospital customers across multiple provincial markets.
Average Trading Volume: 700,433
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.31B
For detailed information about 2190 stock, go to TipRanks’ Stock Analysis page.